[Comparison of mid- and high dosage methylprednisolone pulse therapy in chronic polyarthritis].
Intravenous pulse methylprednisolone of 1000 mg was compared with 250 mg in patients suffering from rheumatoid arthritis. In this prospective open trial no difference could be observed regarding the number of heavily involved joints, morning stiffness, or blood sedimentation rate 2 weeks and 2 months after use of highdose or intermediate dose intravenous methylprednisolone. Medium remission duration was 6 weeks (2-24 weeks). Side effects occurred only rarely; they were transitory and harmless.
Schlumpf
U
U
Medizinische Klinik, Luzern, Schweiz.
Hofmann
P
P
D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D010147:Pain Measurement
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008775:Methylprednisolone
Vergleich einer mittel- und hochdosierten Methylprednisolonstosstherapie bei chronischer Polyarthritis.